TP53 and neoplasm: Using immunohistochemistry tumor markers for LCAMhi cells to evaluate biopsies of NSCLC, this cellular signature was shown to be independent of overall immune cell content but did correlate with the tumor mutational burden, cancer testis antigens, and P53 mutations.